Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 5.1% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ: AMLX) is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases. Today, the stock AMLX experienced a strong bullish movement in the market.

Why is Amylyx Pharmaceuticals going up?

AMLX stock is up 5.1% on Aug 27, 2025 16:35

• AMLX stock surged as investors reacted positively to the company's strategic shift in focus from AMX0035 to avexitide and amyotrophic lateral sclerosis programs.
• The decision to halt the Phase 2b trial for AMX0035 in progressive supranuclear palsy, despite showing no benefit over placebo, was seen as a prudent move by the company to reallocate resources to more promising programs.
• The announcement of a cash runway through 2026 provided investors with confidence in the company's long-term sustainability and growth potential, contributing to the bullish sentiment surrounding AMLX stock today.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

What's Going On With Amylyx Pharma Stock Wednesday? - Amylyx Pharmaceuticals ( NASDAQ:AMLX )

AMX0035 showed no benefit over placebo in progressive supranuclear palsy, leading Amylyx to halt its Phase 2b trial. Amylyx shifts focus to avexitide and amyotrophic lateral sclerosis programs, with cash runway through 2026.

https://www.benzinga.com/news/health-care/25/08/47364006/amylyx-halts-rare-brain-disorder-drug-program-after-disappointing-trial

Trending Today

Charter Communications Inc. ($CHTR) Stock Forecast: Up 5.1% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 5.0% Today

Ralph Lauren Corporation ($RL) Stock Forecast: Down 0.6% Today

Astera Labs Inc ($ALAB) Stock Forecast: Up 5.1% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Down 1.5% Today

Uber Technologies Inc. ($UBER) Stock Forecast: Down 5.0% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 2.7% Today

Eaton Corporation PLC ($ETN) Stock Forecast: Down 3.3% Today

Citizens Financial Group Inc. ($CFG) Stock Forecast: Up 3.4% Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Up 5.3% Today

Amylyx Pharmaceuticals Price History

17.08.2024 - AMLX Stock was up 10.3%

• Recent executive purchases of shares in Reneo Pharmaceuticals and other stocks priced below $5 could signal optimism towards the pharmaceutical sector, potentially benefiting similar companies like AMLX.
• The market's bullish trend, reflected in the Dow Jones index, likely created a favorable atmosphere for small-cap stocks such as AMLX to perform well.
• The insider buying activity may have been viewed by investors and traders as a show of support for the industry, leading to increased interest in AMLX and driving its positive movement.

27.07.2025 - AMLX Stock was up 5.1%

• AMLX stock surged as investors reacted positively to the company's strategic shift in focus from AMX0035 to avexitide and amyotrophic lateral sclerosis programs.
• The decision to halt the Phase 2b trial for AMX0035 in progressive supranuclear palsy, despite showing no benefit over placebo, was seen as a prudent move by the company to reallocate resources to more promising programs.
• The announcement of a cash runway through 2026 provided investors with confidence in the company's long-term sustainability and growth potential, contributing to the bullish sentiment surrounding AMLX stock today.

25.05.2025 - AMLX Stock was up 9.2%

• AMLX displayed significant bullish movement in the market today.
• The upward trend can be attributed to optimistic analyst views regarding the company's potential PBH treatment, which is estimated to target a $2 billion global market by 2035.
• Investor enthusiasm is likely fueled by the anticipation of Avexitide's Phase 3 trial results in the first half of 2026 and the positive outcomes seen in Phase 2 trials.
• Positive analyst initiations and coverage have also played a role in fostering a favorable outlook on AMLX, signaling increasing confidence in the company's future prospects.

18.10.2024 - AMLX Stock was up 7.1%

• The bullish movement in AMLX could be attributed to positive analyst sentiment and upgrades in the online trading sector, similar to recent developments with other companies in the industry.
• This change in outlook by analysts may have instilled confidence in investors, leading to increased buying activity and driving the stock price higher.
• The overall optimism in the online trading industry, as indicated by the analyst upgrades, likely contributed to the positive momentum seen in AMLX today.

07.04.2025 - AMLX Stock was down 5.7%

• A positive upgrade of Logitech International by a prominent Wall Street analyst possibly drew investor attention away from Amylyx Pharmaceuticals, resulting in a decline in AMLX shares.
• The favorable outlook on Logitech International could have prompted a sector shift, with investors reallocating resources from pharmaceuticals like AMLX to technology-oriented firms.
• The upgrade of Logitech International might have eclipsed any recent developments or announcements concerning Amylyx Pharmaceuticals, contributing to the stock's decline.
• Investors may be adjusting their investment portfolios influenced by changing analyst evaluations, leading to a redirection of focus from AMLX to other companies with more favorable ratings.

14.06.2025 - AMLX Stock was up 5.3%

• AMLX stock surged due to positive results from the Phase 2b trial of their drug avexitide, which showed a significant reduction in hypoglycemic events post-weight loss surgery.
• The promising data from the trial likely boosted investor confidence in the drug's potential success in the market, leading to the bullish movement in AMLX stock.
• The positive news overshadowed other market events such as the drop in PPI and Industrial Production, indicating that investors were primarily focused on the favorable trial results of avexitide.

11.06.2024 - AMLX Stock was up 12.6%

• The purchase of avexitide from Eiger BioPharmaceuticals for $35.1 million elevated investor confidence in Amylyx Pharmaceuticals, resulting in a notable increase in the stock price.
• FDA's Breakthrough Therapy Designation for avexitide in addressing post-bariatric hypoglycemia and congenital hyperinsulinism underscored the drug's potential, drawing heightened interest from investors.
• Anticipation for the Phase 3 trials scheduled in 2025 and positive outcomes from Phase 2 trials further bolstered optimism surrounding Amylyx Pharmaceuticals, driving up the stock price.
• The announcement of an upcoming conference call to discuss the acquisition stoked speculation and market interest in the company, contributing to the positive market movement.

12.02.2025 - AMLX Stock was up 12.4%

• Amylyx Pharmaceuticals (AMLYX) experienced a strong bullish movement.
• The positive market sentiment and the overall bullish trend in the market could have contributed to the surge in AMLYX stock.
• There were no specific negative news related to AMLYX mentioned, indicating that the bullish movement might be more driven by market factors rather than company-specific news.
• Investors might be optimistic about the future prospects of Amylyx Pharmaceuticals, leading to increased buying interest and pushing the stock price higher.

13.07.2024 - AMLX Stock was up 5.0%

• AMLX stock experienced a strong bullish movement today.
• The bullish trend can be attributed to the encouraging data revealed on the effects of AMX0035 on cerebrospinal fluid biomarkers related to Alzheimer's disease pathology and neurodegeneration.
• The positive results from the Phase 2 trial, showing reduced tau levels and engagement of multiple pathological pathways, have likely boosted investor confidence in the potential of AMX0035 as a treatment for neurodegenerative diseases.
• The company's recent financial report for Q2 2024 may have also contributed to the positive sentiment surrounding AMLX stock, indicating a strong pipeline with assets targeting orphan indications and FDA Breakthrough Therapy Designation for one of their drugs.

09.07.2024 - AMLX Stock was up 5.1%

• The recent expansion of its late-stage pipeline with the acquisition of avexitide, a Phase 3-ready asset with FDA Breakthrough Therapy Designation, may have driven the bullish movement in AMLX stock.
• Despite a decline in revenue and net loss in the second quarter, investors appear optimistic about the company's pipeline expansion and progress in trials for avexitide and other assets.
• The market's positivity towards Amylyx Pharmaceuticals' new assets targeting orphan indications likely influenced the bullish movement in AMLX stock today.

08.07.2024 - AMLX Stock was down 5.2%

• Amylyx Pharmaceuticals (AMLYX) experienced a significant decline in revenue and a net loss in their Q2 2024 financial results.
• Despite obtaining Orphan Drug Designation for AMX0035 in Wolfram Syndrome from both the FDA and the European Commission, the market's reaction to the company's overall financial performance was negative.
• The acquisition of avexitide and the drug's Phase 3 readiness with FDA Breakthrough Therapy Designation could not counteract the bearish sentiment influenced by the financial results.
• Investors appear to have concerns about Amylyx Pharmaceuticals' capacity to convert its promising pipeline into sustainable revenue growth, which has contributed to the downward movement in AMLYX stock.

24.05.2025 - AMLX Stock was up 10.1%

• Amylyx Pharmaceuticals (NASDAQ: AMLX) experienced a strong bullish movement today.
• The upsurge in the stock's performance may be linked to a new analyst initiating a favorable outlook on the company.
• Analyst Marcus Cole from UBS commencing coverage on a positive note possibly bolstered investor confidence in AMLX.
• The optimistic analyst outlook likely played a role in driving the bullish momentum in AMLX's stock price during the day.